220 related articles for article (PubMed ID: 19604084)
1. Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers.
Peñas-LLedó EM; Dorado P; Pacheco R; González I; LLerena A
Pharmacogenomics; 2009 Jul; 10(7):1111-20. PubMed ID: 19604084
[TBL] [Abstract][Full Text] [Related]
2. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers.
González I; Peñas-Lledó EM; Pérez B; Dorado P; Alvarez M; LLerena A
Pharmacogenomics; 2008 Jul; 9(7):833-40. PubMed ID: 18597648
[TBL] [Abstract][Full Text] [Related]
3. Psychometric characteristic of the Italian version of the Temperament and Character Inventory--revised, personality, psychopathology, and attachment styles.
Martinotti G; Mandelli L; Di Nicola M; Serretti A; Fossati A; Borroni S; Cloninger CR; Janiri L
Compr Psychiatry; 2008; 49(5):514-22. PubMed ID: 18702939
[TBL] [Abstract][Full Text] [Related]
4. Alexithymia, temperament and character as predictors of psychopathology in patients with major depression.
Conrad R; Wegener I; Imbierowicz K; Liedtke R; Geiser F
Psychiatry Res; 2009 Jan; 165(1-2):137-44. PubMed ID: 19084277
[TBL] [Abstract][Full Text] [Related]
5. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
9. Association between cytochrome P450 2D6 genotype and harm avoidance.
Roberts RL; Luty SE; Mulder RT; Joyce PR; Kennedy MA
Am J Med Genet B Neuropsychiatr Genet; 2004 May; 127B(1):90-3. PubMed ID: 15108188
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis.
Doki K; Homma M; Kuga K; Aonuma K; Kohda Y
Pharmacogenet Genomics; 2012 Nov; 22(11):777-83. PubMed ID: 22941032
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.
Novalbos J; López-Rodríguez R; Román M; Gallego-Sandín S; Ochoa D; Abad-Santos F
J Clin Psychopharmacol; 2010 Oct; 30(5):504-11. PubMed ID: 20814331
[TBL] [Abstract][Full Text] [Related]
12. Influence of personality traits on neuropsychological test performance in toxic encephalopathy cases and healthy referent subjects.
Persson R; Osterberg K; Karlson B; Orbaek P
Neurotoxicology; 2000 Oct; 21(5):667-75. PubMed ID: 11130270
[TBL] [Abstract][Full Text] [Related]
13. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 2D6 polymorphism and character traits.
Suzuki E; Kitao Y; Ono Y; Iijima Y; Inada T
Psychiatr Genet; 2003 Jun; 13(2):111-3. PubMed ID: 12782969
[TBL] [Abstract][Full Text] [Related]
15. Personality profiles and minor affective psychopathology in a non-clinical sample: an empirical verification of Cloninger's theoretical model.
Gurpegui M; Jurado D; Fernández-Molina MC; Moreno-Abril O; Luna JD; Alarcón RD
J Affect Disord; 2009 Dec; 119(1-3):34-42. PubMed ID: 19344955
[TBL] [Abstract][Full Text] [Related]
16. [Effect to the serotonin transporter gene (5-HTT) on personality dimensions in individuals without psychopathology].
Lanzagorta N; Alexanderson-Rosas E; Ricalde A; Gómez Caudillo L; Sosa A; Camarena B; Aguilar A; Fresán A; Apiquián R; Nicolini H
Actas Esp Psiquiatr; 2006; 34(5):303-8. PubMed ID: 16991018
[TBL] [Abstract][Full Text] [Related]
17. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
18. Association study between the -1021C/T polymorphism of the dopamine-beta-hydroxylase gene promoter and personality traits in healthy subjects.
Kamata M; Suzuki A; Matsumoto Y; Shibuya N; Togashi H; Goto K; Otani K
Neurosci Lett; 2009 Oct; 462(1):54-7. PubMed ID: 19560519
[TBL] [Abstract][Full Text] [Related]
19. Reliability and validity of the Italian version of the Temperament and Character Inventory-Revised in an outpatient sample.
Fossati A; Cloninger CR; Villa D; Borroni S; Grazioli F; Giarolli L; Battaglia M; Maffei C
Compr Psychiatry; 2007; 48(4):380-7. PubMed ID: 17560961
[TBL] [Abstract][Full Text] [Related]
20. [Personality factors in depressive disorders: contribution of the psychobiologic model developed by Cloninger].
Pelissolo A; Corruble E
Encephale; 2002; 28(4):363-73. PubMed ID: 12232546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
